Will Lar, 10-15% raw material allocation shifts would be more interesting.
1% pharma to 2% pharma - that's interesting in that it shows the category is growing. I'd consider that evolutionary growth...potentially setting the stage for much more.
AMRN has a ways to go before its actually disruptive. That is the idea with V though - create more value-add.